Ganaxolone in Posttraumatic Stress Disorder (PTSD)

PTSD Clinical Trial

Official title:

A Proof-of-Concept, Double-blind, Randomized, Placebo-controlled Study of Ganaxolone in Posttraumatic Stress Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01339689
• Other study ID #: 1042-0700
• Status: Completed
• Phase: Phase 2
• Start date: April 2011
• Est. completion date: March 2014

Study information

• Verified date: November 2022
• Source: Marinus Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 2 proof-of-concept study is a double-blind, randomized, placebo-controlled, 15-week investigation of ganaxolone versus placebo for the treatment of Posttraumatic Stress Disorder (PTSD). Up to 120 participants will be enrolled and randomized to receive either ganaxolone or placebo for 6 weeks. After 6 weeks of randomized treatment all participants will continue for 6 weeks on ganaxolone. The aim of the study is to assess the efficacy of ganaxolone compared to placebo for the treatment of PTSD symptoms after 6 weeks of treatment using the Clinician-Administered PTSD Rating Scale (CAPS). The second aim of the study is to evaluate the safety and tolerability of ganaxolone in the PTSD population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 112
• Est. completion date: March 2014
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Key Inclusion Criteria:

• Veteran or civilian adult outpatients 18-55 years of age, with primary PTSD as defined by Diagnostic and Statistical manual of Mental Disorders-IV (DSM-IV) for at least 6 months

• Must be in general good health-confirmed by medical history, physical examination, and screening laboratory results

• Negative urine drug screen for drugs of abuse

• Negative urine pregnancy test for females of childbearing potential

• Sexually active participants are required to use a medically acceptable form of birth control

Key Exclusion Criteria

• Clinically unstable medical disease; progressive CNS disorder/disease; history of seizures (except childhood febrile seizure); moderate or severe traumatic brain injury (TBI)

• Females who are pregnant or currently breast feeding

• Current or past psychotic disorder, bipolar Type I disorder, or dementia

• Participants with recent drug abuse or dependency (excluding nicotine and caffeine)

• Participants unwilling to comply with the required alcohol prohibition during the trial

• Current suicidal or homicidal ideation necessitating intervention, and those with a history of suicide attempt in the past 10 years

• Participants with pending litigation related to the traumatic event

• Participants who are unwilling to withhold grapefruit or grapefruit juice for the duration of the study

• Participants receiving psychotherapy without a stable paradigm for at least 3 months

• Non-English speaking participants.

Related Conditions & MeSH terms

• PTSD
• Stress Disorders, Post-Traumatic
• Stress Disorders, Traumatic

Intervention

Drug:
• Ganaxolone
200-600 mg bid, capsules, up to 12 weeks
• Placebo
capsules, bid, up to 12 weeks

Locations

Country	Name	City	State
United States	VA Boston Healthcare Services/ Spaulding Rehabilitation Hospital	Boston	Massachusetts
United States	Charleston VA Medica Center/ Medical University of South Carolina	Charleston	South Carolina
United States	Cincinnati VA Medical Center/ University of Cincinnati	Cincinnati	Ohio
United States	Durham VA Medical Center /Duke University Medical Center	Durham	North Carolina
United States	Manchester VA Medical Center/ Dartmouth College	Manchester	New Hampshire
United States	VA San Diego Healthcare System/ University of California, San Diego	San Diego	California
United States	Washington DC VA Medical Center/ Uniformed Services University of the Health Services	Washington	District of Columbia
United States	White River Junction VA Medical Center/ Dartmouth College	White River Junction	Vermont

Sponsors (3)

Lead Sponsor	Collaborator
Marinus Pharmaceuticals	INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium, U.S. Army Medical Research and Development Command

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Clinician-Administered Posttrautamtic Stress Disorder (PTSD) Scale (CAPS) to Week 6	The CAPS was a structured interview that queries participants about each of the 17 Diagnostic and Statistical manual of Mental Disorders IV (DSM-IV) criteria B, C, and D symptoms of PTSD. Each item has a frequency score (0-4) and intensity score (0-4). The CAPS total score is the sum of frequency and intensity ratings for each item and the score range was 0: no symptoms to 136: severe symptoms. Higher score indicates worse symptoms. Baseline was defined as the Day 0 assessment before study drug infusion. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Week 0) and at Week 2, Week 4 and Week 6
Secondary	Change From Baseline in PTSD Re-Experience Score	The CAPS was a structured interview that queries participants about each of the 17 Diagnostic and Statistical manual of Mental Disorders IV (DSM-IV) criteria B, C, and D symptoms of PTSD. Each item has a frequency score (0-4) and intensity score (0-4). The Re-experience score is the sum of frequency and intensity ratings for items from cluster B and the score range was 0: no symptoms to 40: severe symptoms. Higher score indicates worse symptoms. Baseline was defined as the Day 0 assessment before study drug infusion. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Week 0) and at Week 2, Week 4 and Week 6
Secondary	Change From Baseline in PTSD Avoidance Score	The CAPS was a structured interview that queries participants about each of the 17 Diagnostic and Statistical manual of Mental Disorders IV (DSM-IV) criteria B, C, and D symptoms of PTSD. Each item has a frequency score (0-4) and intensity score (0-4). The Avoidance score is the sum of frequency and intensity ratings for items from cluster C.and the score range was 0: no symptoms to 56: severe symptoms. Higher score indicates worse symptoms. Baseline was defined as the Day 0 assessment before study drug infusion. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Week 0) and at Week 2, Week 4 and Week 6
Secondary	Change From Baseline in PTSD Hyperarousal Score	The CAPS was a structured interview that queries participants about each of the 17 Diagnostic and Statistical manual of Mental Disorders IV (DSM-IV) criteria B, C, and D symptoms of PTSD. Each item has a frequency score (0-4) and intensity score (0-4). The Hyperarousal score is the sum of frequency and intensity ratings for items from cluster D and the score range was 0: no symptoms to 40: severe symptoms. Higher score indicates worse symptoms. Baseline was defined as the Day 0 assessment before study drug infusion. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Week 0) and at Week 2, Week 4 and Week 6
Secondary	Number of Participants With Response to Clinical Global Impression - Improvement (Investigator) (CGI-II) Scale	The CGI-II scale is a 7-point scale where the investigator was required to assess how much the participant's illness has improved or worsened relative to a Baseline state at the beginning of the intervention, and rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. Higher score indicated worse symptoms. The score was grouped into two categories for analysis: Responders=1 or 2, Non-responders=3-7.	Week 2, Week 4 and Week 6
Secondary	Number of Participants With Response to CGI-I Subject Scale Clinical Global Impression - Improvement (Subject) (CGI-IS) Scale	The CGI-IS scale is a 7-point scale where the participant assesses how much the illness has improved or worsened relative to a Baseline state at the beginning of the intervention, and rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. Higher score indicated worse symptoms. The score was grouped into two categories for analysis: Responders=1 or 2, Non-responders=3-7.	Week 2, Week 4 and Week 6
Secondary	Change From Baseline in PTSD Checklist (PCL) Scores	The PCL is a 17-item self-report scale representing all DSM-IV criteria for PTSD, including re-experiencing, avoidance and numbing, and hyperarousal criteria. Each item is scored 1-5 (1=not at all; 2=a little bit; 3=moderately; 4=quite a bit; 5=extremely). The total score is the sum of 17 item scores and ranged from 17: no symptoms to 85: severe symptoms. Higher score indicated worse symptoms. Baseline was defined as the Day 0 assessment before study drug infusion. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Week 0) and at Week 2, Week 4 and Week 6
Secondary	Change From Baseline in Profile of Mood States (POMS) Total Score	The POMS is a factor-analytically derived 65 item self-report inventory with 5-point measures of five dimensions of negative mood: anger/irritability, anxiety/tension, depression/dejection, confusion/bewilderment, and fatigue/inertia, as well as vigor/activity. Total score was calculated as Fatigue + Mood (sum [Confusion, anger, Anxiety/Tension, Depression])- Vigor. Score ranged from 0: no symptoms to 200: severe symptoms; higher score indicated worse symptoms. Baseline was defined as the Day 0 assessment before study drug infusion. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Week 0) and Week 6
Secondary	Change From Baseline in Patient Health Questionnaire (PHQ-9) Score	The PHQ-9 is the nine-item depression scale of the Patient Health Questionnaire. The nine items of the PHQ-9 are based directly on the nine diagnostic criteria for major depressive disorder in the DSM-IV. Each item is scored 0-3 (0=not at all; 1=several days; 2=more than half the days; 3= nearly every day). The total score is the sum of 9 item scores and ranged 0: no depression to 27: severe depression. The higher the total score, the worse the depression. Baseline was defined as the Day 0 assessment before study drug infusion. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Week 0) and Week 6
Secondary	Change From Baseline in Insomnia Severity Index (ISI) Score	The ISI is a self-rated questionnaire assessing the difficulty over the past two weeks with falling to sleep, awakening in the middle of the night, and early morning awakening, as well as the degree to which insomnia impairs daily function. It included 5 items (rst item has 3 sub-questions), so a total of 7 questions. Each question is scored 0-4 (0=none, 1=mild, 2=moderate, 3=severe, 4=very severe). The total score is the sum of 7 item scores and ranged from 0: no symptoms to 28: severe symptoms. Higher score indicated worse symptoms. Baseline was defined as the Day 0 assessment before study drug infusion. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.	Baseline (Week 0) and Week 6
Secondary	Change From Baseline in Connor-Davidson Resilience Scale (CD-RISC) Score	The CD-RISC comprises 25 items, each rated on a 5-point scale (0-4), with higher scores reflecting greater resilience that may be a target for treatment in stress disorders. The total score is the sum of 25 item scores and ranged from 0: no symptoms to 100: worse symptoms. Higher score indicates worse symptoms. Baseline was defined as the Day 0 assessment before study drug infusion. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value	Baseline (Week 0) and Week 6